Clinical Trials Browser

Phase 2 × Recurrence × Immunotherapy × Clear all

NCT04981665 2022-01-05

A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular, Recurrence